$ADN #andromeda
my 2c on this chart - the good, the bad & the ugly
Video done due to a lot of request for this chart in the last couple of days - no FA done, so no idea of any gremlins in the background. Purely TA outlook !
Disclosure - NONE
https://t.co/qHzUl5VS3h
@8020invest@endtwist Nice summary. I'm working my way through the hours of research DFV has on his YouTube and his conviction on $GME is clear to see. I made this infographic to show the events on the timelinev against the share price while following the story.
$MSB $MESO tough day for holders, market doesn't like 50/50 news on COVID ARDS. Watching what $NVS Novartis will do next with their partnership deal. Those who believe in the science, patents and sales outside US, holding and accumulating. 5 minute chart from today.
Number of IPOs that have doubled on day one, per year
2010: 0
2011: 1
2012: 1
2013: 6
2014:6
2015: 5
2016: 1
2017: 1
2018: 1
2019: 3
2020: 19
More on @SquawkCNBC at 8:30 a.m. tomorrow
We've been data driven on #COVID infection rates and will continue to be leading into travel resuming. Test and measure. Airports overseas have rapid test centres, like Canada: https://t.co/wACjpJwXI4
We could see the same here, using TGA approved tests from $AT1.ax
Agree. I'd also add patience to hold once invested, is the most effective way to experience life-changing growth. Doesn't help that many find it harder to do when in substantial profit, as opposed to a loss where 'no loss until I sell' is oft heard.
Two of the toughest tests on the emotional road towards investing ; the patience to wait for the right moment to invest and the courage not to be disillusioned with what we encounter along the journey #StayStrong#SmartTrading
Biotech companies need a different approach to research and analyse as compared to other sectors. Binary test results or approval decisions can impact SP both ways. Conviction on the science for longs is key. $IBX, $MSB, $MESO etc.
$IBX is developing a new medical imaging technology that will detect cancer earlier, with higher specificity and sensitivity than MRI and CT, without harmful radiation. Watch our latest video to learn more about how our #MagSense technology could transform cancer detection:
$ADN Company Presentation by MD James Marsh last week at the NWR Virtual Resource Conference. James updates progress on Concrete testing and busy schedule ahead. https://t.co/jGVzR3lIDR
$MSB $MESO with Novartis global big pharma deal may receive a total of $505 M pending achievement of pre-commercialization milestones for ARDS indications. Mesoblast could receive US$750 Million linked to Sales Milestones. Initial focus #COVID19
$MSB $MESO big pharma deal! Novartis partnership for patented remstemcel-l in #COVID and other ARDS. Global license to develop and produce, may fund 50/50 profit. 50M upfront, 25M in equity. They will fund P3 trial. MSB to retain GVHD rights. Next growth wqve! #stemcells future!